Skip to main content
Dryad

Data from: Epigenetic small molecule screening identifies a new HDACi compound for ameliorating Duchenne muscular dystrophy

Abstract

These data are the original data used to produce the figures, tables, and supplemental information for the manuscript "Epigenetic small molecule screening identifies a new HDACi compound for ameliorating Duchenne muscular dystrophy". In this study, our goal was to identify histone deacetylase inhibitors (HDACi), or other classes of epigenetic small molecules that are beneficial for DMD. Using an established animal model for DMD, the zebrafish dmd mutant strain sapje, we screened a library of over 800 epigenetic small molecules. Our screening identified a new HDACi, SR-4370, that ameliorated dmd mutant zebrafish skeletal muscle degeneration, as well as additional HDACi that have previously been shown to improve dmd zebrafish. We find that a single early treatment of HDACi can ameliorate the muscle phenotype and increase lifespan in dmd zebrafish. Furthermore, we find that HDACi treatments that improve dmd muscle also cause increased histone acetylation in zebrafish larvae. Our results add to the growing evidence that HDACi are promising candidates for treating DMD. Our study also provides further support for the effectiveness of small-molecule screening in dmd zebrafish.